- ROUNDTABLE: Pharmacy’s future in sync with technology
- Coalition of healthcare industry stakeholders address best practices regarding controlled substances
- Senate passes Drug Quality and Security Act
- Study from NCPA sheds new light on med synchronization programs
- EXPERT BLOG: Provider status for pharmacists — one way or another
POINT PLEASANT, W.Va. — Fruth Pharmacy on Friday announced their commitment to replace medications containing pseudoephedrine, a nonprescription decongestant that can be used in the illicit manufacture of methamphetamine, with Nexafed, a PSE product formulated with Impede technology that disrupts the extraction and conversion of PSE to meth.
Currently, medications with 30 mg of PSE will be replaced with other mg amounts being replaced as soon as possible, the 27-store chain stated.
“Fruth Pharmacy has long been an advocate in the fight against methamphetamine production,” stated Lynne Fruth, president and chairman for Fruth Pharmacy. “We were excited about the NPLEx system — a cross-state electronic log system — and Nexafed is another tool we are glad to have.”
“The statistics for meth labs in West Virginia alone is staggering,” added Tim Weber, director of pharmacy administration and procurement at Fruth. “If there’s a way to stop people from using medications sold in our pharmacies to produce meth, then we are interested.”
Nexafed is distributed by Acura Pharmaceuticals.
Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.